C-Kit (CD117) Expression in Patients with Small Cell Lung Cancer
Aim: The tyrosine-kinase receptor c-kit and its ligand stem cell factor (SCF) are coexpressed in many small cell lung cancer (SCLC) cell lines. The aim of this study was to search the role of CD117 (c-kit) overexpression as a prognostic marker in SCLC. Methods: Demographic and clinical data of p...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2015-03-01
|
| Series: | Haseki Tıp Bülteni |
| Subjects: | |
| Online Access: | http://www.hasekidergisi.com/article_8702/C-kit-cd117-Expression-In-Patients-With-Small-Cell-Lung-Cancer |
| Summary: | Aim: The tyrosine-kinase receptor c-kit and its ligand stem cell
factor (SCF) are coexpressed in many small cell lung cancer (SCLC)
cell lines. The aim of this study was to search the role of CD117
(c-kit) overexpression as a prognostic marker in SCLC.
Methods: Demographic and clinical data of patients with
SCLC was registered. C-kit overexpression was evaluated
using immunohistochemistry performed in paraffin-embedded
specimens. Immunostaining data of 87 patients were correlated
with survival and other relevant clinical parameters.
Results: The mean age of the patients was 57.1±9.9 years. Thirtynine
patients (44.8%) had limited disease and 48 patients (55.2%)
had extensive disease. C-kit (+) expression was observed in 24.1%
of 87 patients. The mean survival time for c-kit (+) patients was 10.2
(CI=5.7-14.7) months as compared with the c-kit (-) population in
whom the survival was 14.7 (CI=10.7-18.6) months. The difference
in survival time between c- kit (+) and (-) patients was not statistically
significant (p=0.264).
Conclusion: New prognostic markers and more effective treatment
regimens are needed for SCLC. Our findings may provide an insight
to future clinical trials searching c-kit inhibitors in SCLC. (The Medical
Bulletin of Haseki 2015; 53: 67-71) |
|---|---|
| ISSN: | 1302-0072 2147-2688 |